Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab

Eligibility Criteria

• * Prior radiation therapy or surgery to index lesion.
• * Patients with lymphoma, multiple myeloma, germinomas, seminomas, Wilm's tumors, and Ewing's sarcomas will be excluded.
• * Muscle strength of ≤ 3 out of 5 on neurologic exam that correlates with level of the involved spinal cord.
• * Retropulsed compression fracture.
• * Patients with a contraindication to pembrolizumab.
• * Patients may not be receiving any other investigational agents.
• * Patients with symptomatic, brain metastases, as determined by the study PI, that could confound the neurologic exam, should be excluded.
• * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• * Pregnant women are excluded from this study because both radiation and pembrolizumab can be harmful to the developing fetus. Because there is an unknown but potential risk for adverse events, pregnant women are not allowed to participate in this study, in nursing infants secondary to treatment of the mother with pembrolizumab, breastfeeding should be discontinued.